The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults
Marcovecchio ML, Hendriks AEJ, Delfin C, et al.
Diabetologia. Pub. Online 22 Mar 2024.
Leggi
Breaking news
Effectiveness and safety of empagliflozin: final results from the EMPRISE study
Htoo PT, Tesfaye H, Schneeweiss S, et al.
Diabetologia. Pub. Online 21 Mar 2024.
Leggi
The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis
Zhang Y, Yang D, Jia Q, et al.
Diabetes Obes Metab. Pub. Online 26 Mar 2024.
Leggi
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes
Cariou B, Linge J, Neeland IJ, et al.
Diabetes Obes Metab. Pub. Online 26 Mar 2024.
Leggi
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
Eroglu TE, Coronel R, Souverein PC
Eur Heart J Cardiovasc Pharmacother. 2024;pvae022.
Leggi
Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study
Suzuki Y, Kaneko H, Nagasawa H, et al.
Diabetes Obes Metab. Pub. Online 26 Mar 2024.
Leggi
EMA – The Committee for Medicinal Products for Human Use (CHMP) for the medicinal product Nustendi adopted a new indication as follows: Cardiovascular disease
21/03/2024
Leggi
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression
Rivera FB, Lumbang GNO, Gaid DRM, et al.
Diabetes Obes Metab. Pub. online 20 Mar 2024.
Leggi